Reagents, Tools, and Custom Services for Characterizing Biologic Drug Potency
In this webinar, you will learn about:
- Monoclonal Antibody Therapeutics
- Anti-idiotype (anti-ID) antibodies and the types of anti-ID antibodies
- The various roles of anti-ID antibodies in biologic drug development and characterization
- Effector/target cell products that can be combined with antibody modalities for functional readouts
- ADCP and ADCC products to measure antibody activation
Summary
Evaluating the potential impact of immunogenicity on drug efficacy, safety, and overall patient well-being is critical when developing and characterizing biologic drugs to fulfill regulatory requirements and pave the way for safer and more personalized drug therapies. In this webinar, you will gain valuable insights into the various methods for characterizing and quantifying monoclonal antibody therapeutics. Together we'll also explore immunoassays and reagents for evaluating PD, PK, and immunogenic properties of the antibody drug substance or drug product and ways to identify and differentiate particular antibody drugs manufactured on similar antibody architecture.
Speakers
Nicholas Hess, PhD
Product Manager
Promega
Dr. Nicholas Hess received his degrees from University of Minnesota-Duluth and University of Illinois at Urbana-Champaign, Nicholas Hess has extensive experience in the immunology/cell therapy field as well as in product management.
Renee Salvo, PhD
Product Manager
Rockland
Dr. Renee Salvo received her degrees from King's College, The University of Scranton, and a PhD in Biochemistry from the University of the Sciences in Philadelphia, PA (USA), Renee is a seasoned global product manager focused in the Cell, Gene, and RNA Therapeutics space.